147 related articles for article (PubMed ID: 24623337)
61. [Adenomatoid tumor of the testes--a rare entity. Clinical, diagnostic and therapeutic aspects].
Lehsnau M; Hecht L
Urologe A; 2006 Nov; 45(11):1431-4. PubMed ID: 16933122
[TBL] [Abstract][Full Text] [Related]
62. Unclassified sex cord/gonadal stromal testis tumor with a "pure" spindle cell component: a case report.
Spairani C; Squillaci S; Pitino A; Montefiore F; Fusco W
Pathologica; 2018 Dec; 110(4):302-306. PubMed ID: 30799442
[TBL] [Abstract][Full Text] [Related]
63. Differential expression of WT1 and p53 in serous and endometrioid carcinomas of the endometrium.
Egan JA; Ionescu MC; Eapen E; Jones JG; Marshall DS
Int J Gynecol Pathol; 2004 Apr; 23(2):119-22. PubMed ID: 15084839
[TBL] [Abstract][Full Text] [Related]
64. Sertoliform endometrioid carcinomas of the ovary: a clinicopathologic and immunohistochemical study of 13 cases.
Ordi J; Schammel DP; Rasekh L; Tavassoli FA
Mod Pathol; 1999 Oct; 12(10):933-40. PubMed ID: 10530556
[TBL] [Abstract][Full Text] [Related]
65. WT-1 assists in distinguishing ovarian from uterine serous carcinoma and in distinguishing between serous and endometrioid ovarian carcinoma.
Al-Hussaini M; Stockman A; Foster H; McCluggage WG
Histopathology; 2004 Feb; 44(2):109-15. PubMed ID: 14764054
[TBL] [Abstract][Full Text] [Related]
66. Proteomics-Derived Biomarker Panel Improves Diagnostic Precision to Classify Endometrioid and High-grade Serous Ovarian Carcinoma.
Dieters-Castator DZ; Rambau PF; Kelemen LE; Siegers GM; Lajoie GA; Postovit LM; Köbel M
Clin Cancer Res; 2019 Jul; 25(14):4309-4319. PubMed ID: 30979743
[TBL] [Abstract][Full Text] [Related]
67. Tumors of the fimbriated end of the fallopian tube: a clinicopathologic analysis of 20 cases, including nine carcinomas.
Alvarado-Cabrero I; Navani SS; Young RH; Scully RE
Int J Gynecol Pathol; 1997 Jul; 16(3):189-96. PubMed ID: 9421082
[TBL] [Abstract][Full Text] [Related]
68. A Rare Case of Serous Papillary Ovarian Epithelial Type Carcinoma in Testis: A Rare Testicular Neoplasm.
Abdollahi A; Ensani F; Ayati M; Jahanian S; Eftekhar Javadi A; Khorsand A
J Family Reprod Health; 2019 Jun; 13(2):116-119. PubMed ID: 31988648
[TBL] [Abstract][Full Text] [Related]
69. Immunohistochemical characterization of prototypical endometrial clear cell carcinoma--diagnostic utility of HNF-1β and oestrogen receptor.
Hoang LN; Han G; McConechy M; Lau S; Chow C; Gilks CB; Huntsman DG; Köbel M; Lee CH
Histopathology; 2014 Mar; 64(4):585-96. PubMed ID: 24103020
[TBL] [Abstract][Full Text] [Related]
70. Serous borderline ovarian epithelial type tumor of the testis.
Isharwal S; Khot R; Wu Y; Berger BM; Tandon YK
Int Urol Nephrol; 2024 Jul; 56(7):2275-2276. PubMed ID: 38411792
[No Abstract] [Full Text] [Related]
71. Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma.
Loy TS; Calaluce RD; Keeney GL
Mod Pathol; 1996 Nov; 9(11):1040-4. PubMed ID: 8933513
[TBL] [Abstract][Full Text] [Related]
72. Synchronous ovarian endometrioid adenocarcinoma with a functioning stroma and endometrial endometrioid adenocarcinoma by different loss of heterozygosity findings.
Takai N; Kai K; Tsuno A; Nasu K; Kashima K; Narahara H
Arch Gynecol Obstet; 2011 Oct; 284(4):951-5. PubMed ID: 21046134
[TBL] [Abstract][Full Text] [Related]
73. Strategies for distinguishing low-grade endometrioid and serous carcinomas of endometrium.
Garg K; Soslow RA
Adv Anat Pathol; 2012 Jan; 19(1):1-10. PubMed ID: 22156830
[TBL] [Abstract][Full Text] [Related]
74. [Case of testicular venous hemangioma].
Numakura K; Tsuchiya N; Inoue T; Yuasa T; Matsuura S; Satoh S; Habuchi T
Hinyokika Kiyo; 2007 Jul; 53(7):493-5. PubMed ID: 17702185
[TBL] [Abstract][Full Text] [Related]
75. SATB2 Expression Distinguishes Ovarian Metastases of Colorectal and Appendiceal Origin From Primary Ovarian Tumors of Mucinous or Endometrioid Type.
Moh M; Krings G; Ates D; Aysal A; Kim GE; Rabban JT
Am J Surg Pathol; 2016 Mar; 40(3):419-32. PubMed ID: 26551622
[TBL] [Abstract][Full Text] [Related]
76. Transitional cell-like morphology in ovarian endometrioid carcinoma: morphologic, immunohistochemical, and behavioral features distinguishing it from high-grade serous carcinoma.
Karnezis AN; Aysal A; Zaloudek CJ; Rabban JT
Am J Surg Pathol; 2013 Jan; 37(1):24-37. PubMed ID: 23108017
[TBL] [Abstract][Full Text] [Related]
77. Beta-catenin and E-cadherin expression patterns in high-grade endometrial carcinoma are associated with histological subtype.
Schlosshauer PW; Ellenson LH; Soslow RA
Mod Pathol; 2002 Oct; 15(10):1032-7. PubMed ID: 12379748
[TBL] [Abstract][Full Text] [Related]
78. Immunohistochemical comparison of uterine papillary serous and papillary endometrioid carcinoma: clues to pathogenesis.
Demopoulos RI; Mesia AF; Mittal K; Vamvakas E
Int J Gynecol Pathol; 1999 Jul; 18(3):233-7. PubMed ID: 12092593
[TBL] [Abstract][Full Text] [Related]
79. Molecular Alterations of TP53 are a Defining Feature of Ovarian High-Grade Serous Carcinoma: A Rereview of Cases Lacking TP53 Mutations in The Cancer Genome Atlas Ovarian Study.
Vang R; Levine DA; Soslow RA; Zaloudek C; Shih IeM; Kurman RJ
Int J Gynecol Pathol; 2016 Jan; 35(1):48-55. PubMed ID: 26166714
[TBL] [Abstract][Full Text] [Related]
80. Microcystic, Elongated, and Fragmented Pattern Invasion in Ovarian Endometrioid Carcinoma: Immunohistochemical Profile and Prognostic Implications.
Goldberg A; Hand L; DeCotiis D; Rosenblum N; Chan J
Int J Gynecol Pathol; 2018 Jan; 37(1):44-51. PubMed ID: 28319570
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
